This section includes the key available and published information from a literature search (conducted 12 June 2019 and updated in June 2022).
General reviews
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019 ;30(Suppl_8):viii5-viii15.
Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1: e000023.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
Molecular diagnosis reviews
Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022; 35(3):298-305.
Hsiao SJ, Zehir A, Sireci AN et al. Detection of tumor NTRK gene fusions to identify patients who may benefit from TRK inhibitor therapy. J Mol Diagn 2019. doi: 10.1016/j.jmoldx.2019.03.008. [Epub ahead of print]
Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Path 2019; S1525-1578. doi: 10.1136/jclinpath-2018-205679. [Epub ahead of print]
Solomon JP, Hechtman JF. Detection of NTRK Fusions: Merits and limitations of current diagnostic platforms. Cancer Res 2019 Jul 1;79(13):3163-3168. doi: 10.1158/0008-5472.CAN-19-0372.
Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020 Jan;33(1):38-46.
Therapeutic reviews
Kheder ES, Hong DS. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res 2018; 24: 5807-5814.
Consensus and guidelines
Marchio O, Scaltriti M, Ladanyi M et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019 Sep 1;30(9):1417-1427.
doi: 10.1093/annonc/mdz204.